59
Participants
Start Date
March 18, 2017
Primary Completion Date
October 19, 2017
Study Completion Date
October 19, 2017
GLPG2222 50 mg
Oral tablet(s) containing GLPG2222
GLPG2222 100 mg
Oral tablet(s) containing GLPG2222
Placebo
Matching oral tablet(s) containing placebo
GLPG2222 200 mg
Oral tablet(s) containing GLPG2222
GLPG2222 400 mg
Oral tablet(s) containing GLPG2222
John Hopkins University School of Medicine, Baltimore
Medical University of South Carolina, Charleston
Central Florida Pulmonary Group, Orlando
Child Health Research Unit at UAB, Chatom
Cystic Fibrosis Center of Chicago, Glenview
University of Arkansas for medical Sciences, Little Rock
Maine Medical Center, Portland
UZ Antwerpen, Antwerp
UZ Brussel, Brussels
UZ Gent, Ghent
UZ Leuven, Leuven
AMC Amsterdam, Amsterdam
Erasmus medisch centrum, Rotterdam
Haga Ziekenhuis, The Hague
UMC Utrecht, Utrecht
Mother and child health institute of Serbia, New Belgrade
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitario La Paz, Madrid
Hospital Universitarii Plitecnic La Fe, Valencia
Papworth Hospital, Cambridge
St James University Hospital, Leeds
Liverpool Heart and Chest Hospital, Liverpool
Southampton general Hospital, Southampton
Lead Sponsor
Galapagos NV
INDUSTRY